ロード中...

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer

Mutational testing has moved to the forefront as an integral component in the management of patients with non-small cell lung cancer (NSCLC). Currently there are three targeted therapies (erlotinib, afatinib, and crizotinib) approved by the Food and Drug Administration (FDA) to treat patients with s...

詳細記述

保存先:
書誌詳細
主要な著者: Lammers, Philip E., Lovly, Christine M., Horn, Leora
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4151469/
https://ncbi.nlm.nih.gov/pubmed/24453288
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!